Leptin
- Generic Name
- Leptin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 169494-85-3
- Unique Ingredient Identifier
- Q09SXY6BFI
- Background
Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. These people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of insulin. Thus, obesity develops when people take in more energ...
- Indication
Investigated for use/treatment in lipodystrophy and obesity.
- Associated Conditions
- -
- Associated Therapies
- -
In Vivo Leptin Signaling in Humans After Acute Leptin Administration
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT01275053
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Effects of Metreleptin in Type 1 Diabetes Mellitus
- First Posted Date
- 2010-12-31
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT01268644
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Leptin in the Maintenance of Reduced Body Weight
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT01155180
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Trial of Leptin Replacement Therapy in Patients With Lipodystrophy
- Conditions
- Interventions
- First Posted Date
- 2009-05-11
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT00896298
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Trial of Leptin Administration After Roux-en-Y Gastric Bypass
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2015-11-16
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 31
- Registration Number
- NCT00710814
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Therapeutic Approaches to HAART-Induced Lipodystrophy
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT00461552
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT00362440
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Leptin in Human Energy and Neuroendocrine Homeostasis
- Conditions
- Interventions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 22
- Registration Number
- NCT00265980
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
Leptin and Endothelial Function
- Conditions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2006-06-27
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 15
- Registration Number
- NCT00121433
Low-Dose Leptin and the Formerly-Obese
- First Posted Date
- 2003-11-19
- Last Posted Date
- 2015-06-04
- Target Recruit Count
- 25
- Registration Number
- NCT00073242
- Locations
- 🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.